Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

HemAssist to enter phase III

June 28, 1996

SomatoKine covered under U.S. patent

June 28, 1996

Apolipoprotein B synthesis inhibitors reported

June 28, 1996

Phase III trial for Fortical approved in U.K.

June 28, 1996

C31G research results reported

June 21, 1996

Caverject cleared for marketing in Canada

June 21, 1996

Lilly's Humalog reaches first market

June 21, 1996

Teikoku Hormone reveals novel octadecapeptide

June 21, 1996

Lilly discloses insulin analogues

June 21, 1996

Ceredase approved in Japan

June 21, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...